Mateon Therapeutics Announces Initial Pre-clinical Data on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
70
Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors
  • In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completion
  • Three additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody activity

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced encouraging preliminary data from four different syngeneic mouse models evaluating Mateon’s lead investigational drug CA4P in combination with checkpoint inhibitors.

The most compelling results were found combining Mateon’s CA4P with an anti-CTLA4 antibody in an EMT-6 mammary model. In this study, 7 of 8 mice receiving the combination were tumor free at the study’s completion, compared to 1 of 8 in the CA4P monotherapy arm and 2 of 8 in the anti-CTLA4 antibody monotherapy arm.

Three of four follow-up studies also demonstrated that CA4P combined with immune oncology agents delayed tumor growth. These studies were conducted in a larger tumor EMT-6 mammary model, a C3H mammary model and a CT26 colon model. The results provide additional supportive evidence that CA4P enhances anti-CTLA4 antibody activity, as well as initial evidence that CA4P enhances anti-PD-1 and PD-L1 activity.

“We have seen in numerous earlier studies that CA4P, via vascular disruption, induces rapid and extensive necrotic tumor cell death,” stated William D. Schwieterman, M.D., President and Chief Executive Officer. “By causing this tumor cell necrosis, we believe that CA4P may enhance antigen presentation and T-cell activity within the tumors, increasing the effect of checkpoint inhibitors in tumors which do not respond to the immune oncology agents alone. Based upon the results of our initial pre-clinical studies, we are continuing with additional pre-clinical work in this field. Concurrently, our phase 2/3 FOCUS Study, evaluating CA4P in platinum-resistant ovarian cancer, continues to enroll patients and data from the first interim analysis is expected in April. We are also nearing completion of the 3 rd dose cohort in our study of OXi4503 in acute myeloid leukemia.”

Mateon reminds investors that a webcast of today’s presentation at the 19th Annual BIO CEO & Investor Conference at 5:30 pm eastern time will be available on the company’s website at www.mateon.com in “Events & Presentations” under the “Investors & News” tab. A replay of the webcast will also be available following the completion of the live event.

About Mateon Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.

At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.

Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide. 

Safe Harbor Statement Certain statements in this news release, including, but not limited to, those concerning the pre-clinical data on the combination of CA4P with checkpoint inhibitors, the potential significance of this data and its relation to other clinical and pre-clinical studies are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They can be affected by inaccurate assumptions Mateon might make or by known or unknown risks and uncertainties, including, but not limited to: the uncertainties as to the future success of ongoing and planned clinical trials; the unproven safety and efficacy of products under development or that may be developed in the future; and the sufficiency of the Company’s cash resources to conduct and complete future clinical and pre-clinical trials. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Mateon’s reports to the Securities and Exchange Commission, including Mateon’s reports on Forms 10-Q, 8-K and 10-K. However, Mateon undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

CONTACTS Investors: ir@mateon.com 650-635-7000 Media: JPA Health Communications Nic DiBella nic@jpa.com 617-945-5183

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 141

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 23

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 8

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 149

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 80

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading

Top 5 Most Recently Viewed Articles

Embassy Bancorp, Inc. Reports Strong Financial Growth for Q2

Updated Category News Views 197

Embassy Bancorp, Inc. Financial Results Overview Embassy Bancorp, Inc. (OTCQX: EMYB) has recently released a comprehensive report highlighting its operations and financial achievements for the quarter ended June 30, 2025. The report outlines the ongoing stability and growth of the company, reinforcing its position in the competitive banking landscape. Key Financial...

Continue Reading
Unlocking New Features: Wijmo 2025 v2 by MESCIUS USA, Inc.

Updated Category News Views 200

Wijmo 2025 v2: A Leap Forward in Enterprise Software MESCIUS USA Inc. has officially launched Wijmo 2025 v2, marking the last major release for the year. This version not only promises cutting-edge features but also showcases their commitment to enhancing developer experiences across frameworks. Included in this release is robust support for Angular 20 and Nuxt.js 4,...

Continue Reading
Titan Investors Teams with Corridor for Global Expansion

Updated Category News Views 42

Titan Investors Takes a Bold Leap Forward Alright folks, here's a change in the wind that's got my attention. Titan Investors, a heavyweight in the investment event business, has just locked arms with Corridor Capital. Yeah, we're talking about a private equity firm with a knack for boosting the game of middle-market business services across North America. If you're...

Continue Reading
Examining the Implications of a 'Shadow' Fed Chair Role

Updated Category News Views 166

The Emerging Concept of a ‘Shadow’ Fed Chair There has been growing tension surrounding Chairman Powell, particularly with rising frustration from Donald Trump. Reports indicate that Trump may expedite his decision on Powell's successor, creating anticipation for a so-called 'shadow Fed Chair' who would shape economic opinions until Powell's term concludes in 2026....

Continue Reading
U.S. Postal Service Reports Growth and Financial Improvements

Updated Category News Views 294

U.S. Postal Service Financial Results Overview The U.S. Postal Service has recently shared its financial outcomes for the first quarter of fiscal year 2025, revealing impressive growth metrics that mark a significant turnaround from previous years. Controllable income has doubled to $968 million, a substantial increase from $472 million during the same period last year,...

Continue Reading